Incidental dose distribution to locoregional lymph nodes of breast cancer patients undergoing adjuvant radiotherapy with tomotherapy - is it time to adjust current contouring guidelines to the radiation technique?


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
01 Aug 2019
Historique:
received: 17 12 2018
accepted: 26 06 2019
entrez: 3 8 2019
pubmed: 3 8 2019
medline: 10 1 2020
Statut: epublish

Résumé

Along with breast-conserving surgery (BCS), adjuvant radiotherapy (RT) of patients with early breast cancer plays a crucial role in the oncologic treatment concept. Conventionally, irradiation is carried out with the aid of tangentially arranged fields. However, more modern and more complex radiation techniques such as IMRT (intensity-modulated radio therapy) are used more frequently, as they improve dose conformity and homogeneity and, in some cases, achieve better protection of adjacent risk factors. The use of this technique has implications for the incidental- and thus unintended- irradiation of adjacent loco regional lymph drainage in axillary lymph node levels I-III and internal mammary lymph nodes (IMLNs). A comparison of a homogeneous "real-life" patient collective, treated with helical tomotherapy (TT), patients treated with 3D conformal RT conventional tangentially arranged fields (3DCRT) and deep inspiration breath hold (3DCRT-DIBH), was conducted. This study included 90 treatment plans after BCS, irradiated in our clinic from January 2012 to August 2016 with TT (n = 30) and 3D-CRT (n = 30), 3DCRT DIBH (n = 30). PTVs were contoured at different time points by different radiation oncologists (> 7). TT was performed with a total dose of 50.4 Gy and a single dose of 1.8 Gy with a simultaneous integrated boost (SIB) to the tumor cavity (TT group). Patients irradiated with 3DCRT/3DCRT DIBH received 50 Gy à 2 Gy and a sequential boost. Contouring of lymph drainage routes was performed retrospectively according to RTOG guidelines. Average doses (DMean) in axillary lymph node Level I/Level II/Level III were 31.6 Gy/8.43 Gy/2.38 Gy for TT, 24.0 Gy/11.2 Gy/3.97 Gy for 3DCRT and 24.7 Gy/13.3 Gy/5.59 Gy for 3DCRT-DIBH patients. Internal mammary lymph nodes (IMLNs) Dmean were 27.8 Gy (TT), 13.5 Gy (3DCRT), and 18.7 Gy (3DCRT-DIBH). Comparing TT to 3DCRT-DIBH dose varied significantly in all axillary lymph node levels and the IMLNs. Comparing TT to 3DCRT significant dose difference in Level I and IMLNs was observed. Dose applied to locoregional lymph drainage pathways varies comparing tomotherapy plans to conventional tangentially arranged fields. Studies are warranted whether dose variations influence loco-regional spread and must have implications for target volume definition guidelines.

Identifiants

pubmed: 31370876
doi: 10.1186/s13014-019-1328-7
pii: 10.1186/s13014-019-1328-7
pmc: PMC6676557
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135

Références

Lancet. 1999 May 15;353(9165):1641-8
pubmed: 10335782
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):327-33
pubmed: 10802356
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):199-204
pubmed: 11163515
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):69-73
pubmed: 11516853
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):358-64
pubmed: 15667953
Jpn J Clin Oncol. 2008 Feb;38(2):158-63
pubmed: 18216025
Breast Cancer Res Treat. 2009 Feb;113(3):577-83
pubmed: 18330695
Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3
pubmed: 20739842
Br J Radiol. 2010 Dec;83(996):1072-6
pubmed: 21088091
Cancer. 2012 Apr 15;118(8):1994-2003
pubmed: 21882186
Tumori. 2011 Jul-Aug;97(4):498-502
pubmed: 21989440
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Cancer. 1990 Dec 15;66(12):2498-502
pubmed: 2249190
Radiat Oncol. 2012 Dec 14;7:211
pubmed: 23241224
Ann Oncol. 2013 Aug;24(8):2023-8
pubmed: 23616280
Breast. 2013 Dec;22(6):1125-9
pubmed: 24012148
Strahlenther Onkol. 2014 Jan;190(1):5-7
pubmed: 24253182
Strahlenther Onkol. 2014 Apr;190(4):342-51
pubmed: 24638236
Acta Oncol. 2014 Aug;53(8):1027-34
pubmed: 24957557
J Clin Oncol. 2014 Nov 10;32(32):3600-6
pubmed: 25135994
Oncotarget. 2015 Jul 20;6(20):18183-91
pubmed: 26082440
N Engl J Med. 2015 Jul 23;373(4):307-16
pubmed: 26200977
N Engl J Med. 2015 Jul 23;373(4):317-27
pubmed: 26200978
J Clin Oncol. 2016 Feb 1;34(4):297-9
pubmed: 26628473
Radiat Oncol. 2015 Dec 30;10:264
pubmed: 26715382
J Natl Compr Canc Netw. 2016 Mar;14(3):324-54
pubmed: 26957618
Tumori. 2016 Aug 3;102(4):409-13
pubmed: 27002946
Medicine (Baltimore). 2016 Jun;95(26):e4036
pubmed: 27368030
Radiol Bras. 2016 May-Jun;49(3):170-5
pubmed: 27403017
Int J Breast Cancer. 2016;2016:8576357
pubmed: 27525123
Radiother Oncol. 2017 May;123(2):282-287
pubmed: 28351523
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):263-269
pubmed: 29066123
Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1575-82
pubmed: 3759582
Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):353-9
pubmed: 7836089
N Engl J Med. 1997 Oct 2;337(14):949-55
pubmed: 9395428
Semin Radiat Oncol. 1998 Jul;8(3):224-8
pubmed: 9634499

Auteurs

Michael Mayinger (M)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany. michael.mayinger@tum.de.
Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland. michael.mayinger@tum.de.

Kai Joachim Borm (KJ)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.

Constantin Dreher (C)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.

Hendrik Dapper (H)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.

Marciana-Nona Duma (MN)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.
Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, D-85764, Oberschleißheim, Germany.

Markus Oechsner (M)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.

Severin Kampfer (S)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.

Stephanie Elisabeth Combs (SE)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.
Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, D-85764, Oberschleißheim, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.

Daniel Habermehl (D)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, D-81675, Munich, Germany.
Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, D-85764, Oberschleißheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH